Compile Data Set for Download or QSAR
Report error Found 253 Enz. Inhib. hit(s) with all data for entry = 9872
TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421410(US10508086, Example 1 | US10995073, Example 1)
Affinity DataEC50:  9.41E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421411(US10508086, Example 2 | US10995073, Example 2)
Affinity DataEC50:  5.00E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421412(US10508086, Example 3 | US10995073, Example 3)
Affinity DataEC50:  8.28E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421413(US10508086, Example 4 | US10995073, Example 4)
Affinity DataEC50:  2.91E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421414(US10508086, Example 5 | US10995073, Example 5)
Affinity DataEC50:  6.76E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421415(US10508086, Example 6 | US10995073, Example 6)
Affinity DataEC50:  8.32E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421416(US10508086, Example 7 | US10995073, Example 7)
Affinity DataEC50:  9.79E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421417(US10508086, Example 8 | US10995073, Example 8)
Affinity DataEC50:  4.51E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421418(US10508086, Example 9 | US10995073, Example 9)
Affinity DataEC50:  4.04E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421419(US10508086, Example 10 | US10995073, Example 10)
Affinity DataEC50:  8.42E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421420(US10508086, Example 11 | US10995073, Example 11)
Affinity DataEC50:  4.67E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421421(US10508086, Example 12 | US10995073, Example 12)
Affinity DataEC50:  8.29E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421422(US10508086, Example 13 | US10995073, Example 13)
Affinity DataEC50:  7.12E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421423(US10508086, Example 14 | N-(1-Methylcyclopropyl)-1...)
Affinity DataEC50:  4.28E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421424(US10508086, Example 15 | US10995073, Example 15)
Affinity DataEC50:  6.59E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421425(US10508086, Example 16 | US10995073, Example 16)
Affinity DataEC50:  3.39E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421426(US10508086, Example 17 | US10995073, Example 17)
Affinity DataEC50:  4.78E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421427(US10508086, Example 18 | US10995073, Example 18)
Affinity DataEC50:  7.56E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421428(US10508086, Example 19 | US10995073, Example 19)
Affinity DataEC50:  5.36E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421429(US10508086, Example 20 | US10995073, Example 20)
Affinity DataEC50:  3.50E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421430(US10508086, Example 21 | N-(1-Methylcyclopropyl)-1...)
Affinity DataEC50:  5.23E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421431(US10508086, Example 22 | US10995073, Example 22)
Affinity DataEC50:  9.18E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421432(US10508086, Example 23 | US10995073, Example 23)
Affinity DataEC50:  8.83E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421433(US10508086, Example 24 | US10995073, Example 24)
Affinity DataEC50:  2.80E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421434(US10508086, Example 25 | N-(1-Methylcyclopropyl)-1...)
Affinity DataEC50:  8.92E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421435(US10508086, Example 26 | US10995073, Example 26)
Affinity DataEC50:  6.99E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421436(US10508086, Example 27 | US10995073, Example 27)
Affinity DataEC50:  925nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421437(US10508086, Example 28 | US10995073, Example 28)
Affinity DataEC50:  352nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421438(US10508086, Example 29 | US10995073, Example 29)
Affinity DataEC50:  4.46E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421439(US10508086, Example 30 | US10995073, Example 30)
Affinity DataEC50:  9.57E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421440(US10508086, Example 31 | US10995073, Example 31)
Affinity DataEC50:  4.91E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421441(US10508086, Example 32 | US10995073, Example 32)
Affinity DataEC50:  6.86E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421442(US10508086, Example 33 | US10995073, Example 33)
Affinity DataEC50:  6.31E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421443(US10508086, Example 34 | US10995073, Example 34)
Affinity DataEC50:  6.21E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421444(US10508086, Example 35 | US10995073, Example 35)
Affinity DataEC50:  7.69E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421445(US10508086, Example 36 | US10995073, Example 36)
Affinity DataEC50:  6.17E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421446(US10508086, Example 37 | US10995073, Example 37)
Affinity DataEC50:  3.15E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421447(US10508086, Example 38 | US10995073, Example 38)
Affinity DataEC50:  5.72E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421448(US10508086, Example 39 | US10995073, Example 39)
Affinity DataEC50:  3.74E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421449(US10508086, Example 40 | US10995073, Example 40)
Affinity DataEC50:  6.30E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421450(US10508086, Example 41 | US10995073, Example 41)
Affinity DataEC50:  5.77E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421451(US10508086, Example 42 | US10995073, Example 42)
Affinity DataEC50:  2.35E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421452(US10508086, Example 43 | US10995073, Example 43)
Affinity DataEC50:  5.25E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421453(US10508086, Example 44 | US10995073, Example 44)
Affinity DataEC50:  3.35E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421454(US10508086, Example 45 | US10995073, Example 45)
Affinity DataEC50:  3.20E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421455(US10508086, Example 46 | US10995073, Example 46)
Affinity DataEC50:  9.75E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421456(US10508086, Example 47 | US10995073, Example 47)
Affinity DataEC50:  5.72E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421457(US10508086, Example 48 | US10995073, Example 48)
Affinity DataEC50:  7.83E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421458(US10508086, Example 49 | US10995073, Example 49)
Affinity DataEC50:  5.07E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetPoly(ADP-ribose) glycohydrolase(Human)
Cancer Research Technology

US Patent
LigandPNGBDBM421459(US10508086, Example 50 | US10995073, Example 50)
Affinity DataEC50:  4.91E+3nMAssay Description:PARG In vitro assays were conducted in a total volume of 15 ul in a standard 384 well format. 5 ul of Human Full Length PARG (Produced internally by ...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Displayed 1 to 50 (of 253 total ) | Next | Last >>
Jump to: